$599

Altimmune Initiates PERFORMA; Amylyx Launches PBH Awareness Campaign; Vertex Q2 ’26 Earnings

Three cardiometabolic-related news items have been observed: Altimmune initiated the pivotal Ph3 PERFORMA trial in F2-F3 MASH (view press release); Amylyx Pharmaceuticals launched a post-bariatric hypoglycemia education website (view article); and Vertex Pharmaceuticals hosted its Q2 ’26 earnings call, disclosing a new T1DM cell therapy program (view press release; slides).

This content is for Read Less members only.
Already a member? Log in here